The primary outcome was all-cause mortality within 28 days after randomization; further analyses were specified at 6 months. Secondary outcomes were the time until discharge from the hospital and, among patients not receiving invasive mechanical ventilation at the time of randomization, subsequent receipt of invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death. Other prespecified clinical outcomes included cause-specific mortality, receipt of renal hemodialysis or hemofiltration, major cardiac arrhythmia (recorded in a subgroup), and receipt and duration of ventilation.
>
Procedures
>
Therapeutic or Preventive Procedure
>
Hemofiltration
Hemofiltration
Hemofiltration is a type of renal replacement therapy that involves the removal of waste products, excess water, and electrolytes from the blood using a semipermeable membrane.
This process, also known as continuous venovenous hemofiltration (CVVH), is often used to treat acute kidney injury or chronic kidney disease.
Hemofiltration can be an effective alternative to hemodialysis, with the potential to provide more precise control over fluid balance and electrolyte levels.
Researchers in this field may utilize PubCompare.ai to optimzie their hemofiltration research process, leveraging AI-driven comparisons to locate the best protocols from literature, pre-prints, and patents, thus enhancing reproducibility and acuracy.
By exploring the power of PubCompare.ai, researchers can take their hemofiltration studies to the next level.
This process, also known as continuous venovenous hemofiltration (CVVH), is often used to treat acute kidney injury or chronic kidney disease.
Hemofiltration can be an effective alternative to hemodialysis, with the potential to provide more precise control over fluid balance and electrolyte levels.
Researchers in this field may utilize PubCompare.ai to optimzie their hemofiltration research process, leveraging AI-driven comparisons to locate the best protocols from literature, pre-prints, and patents, thus enhancing reproducibility and acuracy.
By exploring the power of PubCompare.ai, researchers can take their hemofiltration studies to the next level.
Most cited protocols related to «Hemofiltration»
Cardiac Conduction System Disease
Extracorporeal Membrane Oxygenation
Hemodialysis
Hemofiltration
Kidney
Mechanical Ventilation
Patient Discharge
Patients
Medical records of 291 patients were collected from January 1, 2003 to April 30, 2016. Of these, 28 underwent more than one CRRT treatment run. Final analysis was done by removing duplicates and leaving only the longest CRRT run.
During the study period, patients undergoing CRRT were included and grouped as before SCT (group A) and after SCT (group B). Group A included patients treated from March 2003 to July 2008 and group B those from August 2008 to April 2016. Before SCT, pediatric CRRT was run by occasional operators, but after the SCT began, ICU nurses joined and began to work as the member of SCT. Double-lumen catheters ranging between 6.5 and 13.5 F in diameter (Gambro Healthcare, Lakewood, CO, USA) were inserted into the central veins depending on the child’s age and weight. Polyarylethersulfone hollow-fiber hemofilters (PAES; the Prismaflex® HF20, Gambro Lundia AB, Lund, Sweden) and polyacrilonytrile hollow-fiber hemofilters (① AN69® membrane before the year 2010; the Prismaflex® M-10/60/100, Gambro Lundia AB, Lund, Sweden; ② AN69® ST membrane since the year 2010; the Prismaflex® ST-60/100, Gambro Lundia AB, Lund, Sweden) were used in all patients, depending on the patient’s weight. HF-20 or M-10 were used in children weighing less than 10 kg; ST-60 or M-60 were used in patients weighing 10–20 kg, and ST-100 or M-100 were used in children weighing more than 20 kg. Commercially prepared bicarbonate-buffered hemofiltration replacement fluid (Hemosol B0; Gambro Healthcare, Seoul, Korea; potassium free), was used as a dialysate and replacement fluid. Potassium chloride (KCl) was added if the patient has a risk of hypokalemia (20 mEq KCl mix in the 5L Hemozol® when serum potassium level ranged from 3.6 to 4.5 mEg/L and 40 mEq KCl mix in the 5L Hemozol® when serum potassium level lowered than 3.6 mEg/L). The blood flow rate was set as 5 mL/kg/min [18 (link)]. The predilution replacement fluid rate or dialysate rate was set at a rate of 2000 mL/1.73 m2/hour [18 (link)]. The mode of CRRT was selected from one of the following, depending on the patient’s status of solute imbalance: continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF). These were determined by the pediatric nephrologist and pediatric intensivist through in-depth discussion.
The time to initiate CRRT was decided by the pediatric intensivist, depending on each patient’s clinical condition, such as anuria, oliguria (<0.5 mL/kg/hour), or positive fluid balance, regardless of administration of high doses of diuretics (furosemide more than 1 mg/kg/hour). Anticoagulation was not administered during CRRT initiation; however, our protocol establishes that if the filter was blocked within 12 hours of CRRT initiation, anticoagulation agents such as continuous heparin or nafamostat mesilate infusion via the pre-blood pump port were used. The percentage of fluid overload at CRRT initiation (%FO) was calculated using the following formula [20 (link)]:
At the initiation of CRRT, the following data were obtained for all patients: sex, age, diagnosis, underlying patient conditions, blood flow rate, use of inotropic agents, anticoagulants, and hours to starting CRRT.
During the study period, patients undergoing CRRT were included and grouped as before SCT (group A) and after SCT (group B). Group A included patients treated from March 2003 to July 2008 and group B those from August 2008 to April 2016. Before SCT, pediatric CRRT was run by occasional operators, but after the SCT began, ICU nurses joined and began to work as the member of SCT. Double-lumen catheters ranging between 6.5 and 13.5 F in diameter (Gambro Healthcare, Lakewood, CO, USA) were inserted into the central veins depending on the child’s age and weight. Polyarylethersulfone hollow-fiber hemofilters (PAES; the Prismaflex® HF20, Gambro Lundia AB, Lund, Sweden) and polyacrilonytrile hollow-fiber hemofilters (① AN69® membrane before the year 2010; the Prismaflex® M-10/60/100, Gambro Lundia AB, Lund, Sweden; ② AN69® ST membrane since the year 2010; the Prismaflex® ST-60/100, Gambro Lundia AB, Lund, Sweden) were used in all patients, depending on the patient’s weight. HF-20 or M-10 were used in children weighing less than 10 kg; ST-60 or M-60 were used in patients weighing 10–20 kg, and ST-100 or M-100 were used in children weighing more than 20 kg. Commercially prepared bicarbonate-buffered hemofiltration replacement fluid (Hemosol B0; Gambro Healthcare, Seoul, Korea; potassium free), was used as a dialysate and replacement fluid. Potassium chloride (KCl) was added if the patient has a risk of hypokalemia (20 mEq KCl mix in the 5L Hemozol® when serum potassium level ranged from 3.6 to 4.5 mEg/L and 40 mEq KCl mix in the 5L Hemozol® when serum potassium level lowered than 3.6 mEg/L). The blood flow rate was set as 5 mL/kg/min [18 (link)]. The predilution replacement fluid rate or dialysate rate was set at a rate of 2000 mL/1.73 m2/hour [18 (link)]. The mode of CRRT was selected from one of the following, depending on the patient’s status of solute imbalance: continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF). These were determined by the pediatric nephrologist and pediatric intensivist through in-depth discussion.
The time to initiate CRRT was decided by the pediatric intensivist, depending on each patient’s clinical condition, such as anuria, oliguria (<0.5 mL/kg/hour), or positive fluid balance, regardless of administration of high doses of diuretics (furosemide more than 1 mg/kg/hour). Anticoagulation was not administered during CRRT initiation; however, our protocol establishes that if the filter was blocked within 12 hours of CRRT initiation, anticoagulation agents such as continuous heparin or nafamostat mesilate infusion via the pre-blood pump port were used. The percentage of fluid overload at CRRT initiation (%FO) was calculated using the following formula [20 (link)]:
At the initiation of CRRT, the following data were obtained for all patients: sex, age, diagnosis, underlying patient conditions, blood flow rate, use of inotropic agents, anticoagulants, and hours to starting CRRT.
Anticoagulants
Anuria
Bicarbonates
BLOOD
Blood Circulation
Cardiac Arrest
Catheters
Child
Continuous Venovenous Hemodiafiltration
Continuous Venovenous Hemodialysis
Diagnosis
Dialysis Solutions
Diuretics
Fibrosis
Fluid Balance
Furosemide
Hemofiltration
Heparin
Infusion Pump
nafamostat mesilate
Nephrologists
Nurses
Oliguria
Patients
phenyl-2-aminoethyl sulfide
Potassium
Serum
Tissue, Membrane
Veins
Venovenous Hemofiltration, Continuous
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone, hydroxychloroquine, lopinavir–ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin, and casirivimab plus imdevimab) have been published previously.3 (link), 5 (link), 18 (link), 19 (link), 20 (link), 21 (link), 22 (link), 23 (link), 24 (link) The trial is underway at 177 hospital organisations in the UK supported by the National Institute for Health Research Clinical Research Network (appendix pp 3–27 ). Of these, 159 UK hospitals enrolled participants in the evaluation of baricitinib. The trial is coordinated by the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the trial sponsor. The trial is done in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency and the Cambridge East Research Ethics Committee (reference 20/EE/0101). The protocol and statistical analysis plan are available in the appendix (pp 68–145) with additional information available on the study website.
Patients aged at least 2 years admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at substantial risk if they were to participate in the trial. Patients were ineligible for the comparison of baricitinib versus usual care if younger than 2 years, had estimated glomerular filtration rate (eGFR) of less than 15 mL/min per 1·73 m2 or were on dialysis or haemofiltration, had a neutrophil count of less than 0·5 × 109 per L, had evidence of active tuberculosis infection, or were pregnant or breastfeeding. Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.
Patients aged at least 2 years admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at substantial risk if they were to participate in the trial. Patients were ineligible for the comparison of baricitinib versus usual care if younger than 2 years, had estimated glomerular filtration rate (eGFR) of less than 15 mL/min per 1·73 m2 or were on dialysis or haemofiltration, had a neutrophil count of less than 0·5 × 109 per L, had evidence of active tuberculosis infection, or were pregnant or breastfeeding. Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.
Aspirin
Azithromycin
baricitinib
casirivimab-imdevimab
Colchicine
Conferences
COVID 19
Dexamethasone
Dialysis
Ethics Committees, Research
Glomerular Filtration Rate
Hemofiltration
Hydroxychloroquine
lopinavir-ritonavir drug combination
Neutrophil
Patients
Pharmaceutical Preparations
Plasma
Population Health
tocilizumab
Tuberculosis
Youth
This is a prospective cohort study of maintenance hemodialysis patients using JRDR data. JSDT has been conducting annual surveys of dialysis facilities in Japan since 1968. The JRDR data from 2008 to 2009 were used in this study. This study was approved by the ethics committee of JSDT and was exempt from the need to obtain informed consent from participants (JSDT No. 6). The data were analyzed anonymously. The study was performed in accordance with the relevant guidelines and the Declaration of Helsinki of 1975 as revised in 1983.
The subjects of this study were the 275553 patients (Fig 1 ).
The sample size was evaluated by alpha error and power. The exclusion criteria were as follows: patients younger than twenty years; patients on hemodiafiltration, hemofiltration, or peritoneal dialysis; patients with missing values or outlier values of laboratory data; patients who had a limb amputated; and patients with a hemodialysis vintage of less than one year. Thus, 96698 subjects were included in the analysis. The included subjects were randomly classified into two groups to obtain (1) a dataset for the development of NRI (development dataset, 48349) and (2) a dataset for validation of NRI (validation dataset, 48349). The sample size was evaluated to maximize statistical power.
The baseline data were as follows: gender; age; history of cardiovascular disease (CVD); diabetes mellitus (DM) as a cause of end stage renal disease (ESRD); vintage; body mass index (BMI); serum albumin, total cholesterol, creatinine, phosphorus, and C reactive protein (CRP) levels; hemoglobin level; normalized protein catabolic rate (nPCR) and Kt/V. The laboratory data were measured before hemodialysis, and BMI was measured on the basis of weight measured after hemodialysis. The outcome was death including all-cause death and CVD- and infection-caused deaths within one year.
The subjects of this study were the 275553 patients (
The sample size was evaluated by alpha error and power. The exclusion criteria were as follows: patients younger than twenty years; patients on hemodiafiltration, hemofiltration, or peritoneal dialysis; patients with missing values or outlier values of laboratory data; patients who had a limb amputated; and patients with a hemodialysis vintage of less than one year. Thus, 96698 subjects were included in the analysis. The included subjects were randomly classified into two groups to obtain (1) a dataset for the development of NRI (development dataset, 48349) and (2) a dataset for validation of NRI (validation dataset, 48349). The sample size was evaluated to maximize statistical power.
The baseline data were as follows: gender; age; history of cardiovascular disease (CVD); diabetes mellitus (DM) as a cause of end stage renal disease (ESRD); vintage; body mass index (BMI); serum albumin, total cholesterol, creatinine, phosphorus, and C reactive protein (CRP) levels; hemoglobin level; normalized protein catabolic rate (nPCR) and Kt/V. The laboratory data were measured before hemodialysis, and BMI was measured on the basis of weight measured after hemodialysis. The outcome was death including all-cause death and CVD- and infection-caused deaths within one year.
Cardiovascular Diseases
Cholesterol
C Reactive Protein
Creatinine
Diabetes Mellitus
Dialysis
Ethics Committees
Gender
Hemodiafiltration
Hemodialysis
Hemofiltration
Hemoglobin
Index, Body Mass
Infection
Kidney Failure, Chronic
Patients
Peritoneal Dialysis
Phosphorus
Proteins
Serum Albumin
Youth
This prospective observational study was performed in the 35-bed Department of Intensive Care at Erasme University Hospital, Brussels. The study was approved by the ethics committee of Erasme Hospital (reference P2013/108), who waived the need for informed consent due to the observational nature of the study.
All adult patients admitted to the department during 2012 were included if they met the following criteria: (a) age older than 15 years; (b) suspected or proven infection supported by clinical evidence and/or positive bacteriological data, and treated with antibiotics; (c) sepsis-associated organ failure, as defined by a Sequential Organ Failure Assessment (SOFA) subscore of 3 or 4 [13 (link)]; (d) duration of intensive care unit (ICU) stay of more than 48 hours. Three patients readmitted for a different sepsis episode were considered as new patients. Septic shock was defined using standard criteria [1 (link)].
Patients were treated according to department policy using the Surviving Sepsis Campaign guidelines [3 (link)]. Fluid administration was initially guided by a combination of echocardiography, signs of fluid responsiveness in mechanically ventilated patients who were receiving sedative agents, and repeated measurements of cardiac filling [14 (link)]. Subsequently, the amount of intravenous fluid given was guided by a number of variables, including arterial pressure, heart rate, cardiac filling pressures and volumes, cardiac output, central venous oxygen saturations and blood lactate levels [3 (link)].
Demographic and bacteriologic data were collected from all patients, as were all relevant elements needed to calculate the SOFA score. We also noted the duration of hospital stay before ICU admission, medical or surgical (emergency or elective) reason for admission, origin (home, ambulance, emergency room, hospital ward, other hospital), length of ICU stay, ICU and hospital survival. The use of diuretics or renal replacement therapy (RRT, hemofiltration and/or hemodialysis) was also noted.
Daily fluid intake was calculated as the sum of all intravenous and oral fluids. The daily fluid output was calculated as the sum of the volumes of urine output, ultrafiltration fluid, drain fluid, and estimated gastrointestinal losses (including stools only in the presence of profound diarrhea). Insensitive losses were not taken into account because they are difficult to assess reliably. Daily fluid balance (according to baseline patient weight) was calculated by subtracting the total fluid output from the total intake. Day 1 was defined as the time between ICU admission and the next morning.
All adult patients admitted to the department during 2012 were included if they met the following criteria: (a) age older than 15 years; (b) suspected or proven infection supported by clinical evidence and/or positive bacteriological data, and treated with antibiotics; (c) sepsis-associated organ failure, as defined by a Sequential Organ Failure Assessment (SOFA) subscore of 3 or 4 [13 (link)]; (d) duration of intensive care unit (ICU) stay of more than 48 hours. Three patients readmitted for a different sepsis episode were considered as new patients. Septic shock was defined using standard criteria [1 (link)].
Patients were treated according to department policy using the Surviving Sepsis Campaign guidelines [3 (link)]. Fluid administration was initially guided by a combination of echocardiography, signs of fluid responsiveness in mechanically ventilated patients who were receiving sedative agents, and repeated measurements of cardiac filling [14 (link)]. Subsequently, the amount of intravenous fluid given was guided by a number of variables, including arterial pressure, heart rate, cardiac filling pressures and volumes, cardiac output, central venous oxygen saturations and blood lactate levels [3 (link)].
Demographic and bacteriologic data were collected from all patients, as were all relevant elements needed to calculate the SOFA score. We also noted the duration of hospital stay before ICU admission, medical or surgical (emergency or elective) reason for admission, origin (home, ambulance, emergency room, hospital ward, other hospital), length of ICU stay, ICU and hospital survival. The use of diuretics or renal replacement therapy (RRT, hemofiltration and/or hemodialysis) was also noted.
Daily fluid intake was calculated as the sum of all intravenous and oral fluids. The daily fluid output was calculated as the sum of the volumes of urine output, ultrafiltration fluid, drain fluid, and estimated gastrointestinal losses (including stools only in the presence of profound diarrhea). Insensitive losses were not taken into account because they are difficult to assess reliably. Daily fluid balance (according to baseline patient weight) was calculated by subtracting the total fluid output from the total intake. Day 1 was defined as the time between ICU admission and the next morning.
Adult
Ambulances
Antibiotics, Antitubercular
BLOOD
Cardiac Output
Diarrhea
Diuretics
Echocardiography
Emergencies
Ethics Committees, Clinical
Feces
Fluid Balance
Heart
Hemodialysis
Hemofiltration
Infection
Intensive Care
Lactates
Operative Surgical Procedures
Oxygen Saturation
Patients
Rate, Heart
Sedatives
Septicemia
Septic Shock
Ultrafiltration
Urine
Veins
Most recents protocols related to «Hemofiltration»
The diagnosis of postoperative AKI stage 3 was based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria (12 (link)): a threefold increase or more above baseline or an increase in serum creatinine (sCr) to ≥ 4.0 mg/dl (≥ 353.6 mmol/l) or the initiation of renal replacement therapy (RRT) or, in patients under 18 years of age, a decrease in estimated glomerular filtration rate (eGFR) to <35 ml/min per 1.73 m2 (Table 1 ). The diagnosis of ATAAD was confirmed by a contrast-enhanced computed tomography (CT) scan, with the onset of symptoms onset within 48 h. Intraoperative bleeding was defined as blood loss that was collected and quantified using intraoperative cell salvage and surgical gauze swabs. Continuous RRT was defined as the need for continuous hemofiltration or hemodialysis after surgery.
Cells
Continuous Renal Replacement Therapy
Creatinine
Diagnosis
Glomerular Filtration Rate
Hemodialysis
Hemofiltration
Hemorrhage
Kidney Diseases
Operative Surgical Procedures
Patients
Radionuclide Imaging
Renal Replacement Therapy
Serum
X-Ray Computed Tomography
Data were collected from all adult patients who underwent cardiac surgery at the University Hospital of North Midlands NHS Trust between April 2012 and May 2019 (inclusive). Thoracic aortic and any ‘emergency’/‘salvage’ procedures data were excluded from the initial search of the database. We were interested in four primary outcome variables observed within 30 days of the operation: (1) Death, (2) New haemofiltration/dialysis (HF). (3) New post-operative neurological deficit, and (4) Return to theatre for thoracic bleeding or tamponade. Outcomes which are defined as ‘subjective processes of care/resource use’ such as: use of post operative inotropic/mechanical ventricular support, post-operative red blood cell transfusion and length of post operative stay are provided in the Additional file 1 . Definitions of ‘elective’/‘urgent’ and the above outcomes are those specified by the National Institute for Cardiovascular Outcomes Research (NICOR) [7 ]. Pre-operative variables are those specified by the EuroSCORE (ES) [8 ]. ES was calculated via the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS). Duration of operation (DOO) was defined as the length of time taken from ‘knife to skin’ until application of the final wound dressings. There were 182 patient records with inconsistencies or missing values in the original data set and so data from these patients were excluded from the study.
Adult
Cardiovascular System
Dialysis
Dressings
Emergencies
Heart Ventricle
Hemofiltration
Inclusion Bodies
Patients
Red Blood Cell Transfusion
Scott Syndrome
Skin
Surgery, Day
Surgical Procedure, Cardiac
Thoracic Aorta
Wounds
Mortality of patients
New-onset organ failure, defined as organ failure after randomization (not present at any time before randomization). Including respiratory failure (PaO2/FiO2 ≦ 300, or requirement of mechanical ventilation), circulatory failure (systolic blood pressure < 90 mmHg, despite adequate fluid resuscitation, or requirement for inotropic catecholamine support) and renal failure (creatinine level > 177 μmol/L after rehydration or new need for hemofiltration or hemodialysis
Intra-abdominal pressure, measured indirect using bladder pressure [37 (link)] every day after enrollment
Timing of EN, defined as time from randomization to the initiation of tolerated EN
Borborygmus, measured every day by member of study team
Occurrence of abdominal infection, based on the diagnosis when discharging
The proportion of adverse events and serious adverse events identified in both groups
Health economics, including length of ICU stay, length of hospital study, and total cost in hospital, documented based on hospital information system
Abdomen
Catecholamines
Creatinine
Diagnosis
Hemofiltration
Intraabdominal Infections
Kidney Failure
Mechanical Ventilation
Pressure
Rehydration
Respiratory Failure
Resuscitation
Shock
Systolic Pressure
Urinary Bladder
Inclusion criteria for the critically ill patient cohort were defined as follows: age ≥ 75 years admitted to the ICU, mechanical ventilation during the first 48 h with a fraction of inspired oxygen (FiO2) <0.6 and respiratory rate ≤30 per minute. Exclusion criteria were continuous hemofiltration, intermittent dialysis, inhaled NO therapy, bronchopleural fistula, respiratory or severe hemodynamic instability (defined as mean arterial pressure below 65 mmHg despite vasopressor therapy), chest drainage, and the administration of excess amounts of carbohydrates. The level of consciousness was documented using the Richmond agitation and sedation scale (RASS) [19 (link)]. All consecutive patients during a 24-month period were assessed for eligibility. Baseline patient characteristics, including medication, nutrition and physiologic variables, were recorded for the day of REE measurement along with data for acute physiology and chronic health evaluation II (APACHE II) [20 (link)], sequential organ failure assessment (SOFA) score [21 (link)], and nutrition risk in the critically ill patient (NUTRIC) score [22 (link)]. Indirect calorimetry was conducted with the open-circuit, side-stream M-CVOX IC device (Datex-Ohmeda, Helsinki, Finland). As per the clinical standard, a resting period with avoidance of physical activity of at least 30 min preceded all measurements. Before each measurement, the endotracheal tube cuff was checked in order to avoid a leak >10% ((inspiratory tidal volume [mL] − expiratory tidal volume [mL])/inspiratory tidal volume [mL] × 100)) and a 5-min warm up period with automated calibration was performed according to the manufacturer’s specifications. The measurement of REE was performed for 45 min after reaching equilibrium for at least five minutes, with a variation in gas exchange and a respiratory quotient of less than ±10%. All measurements were carried out with patients lying in supine position. Individual mREE was compared to cREE using established PE from Cerra et al. (ACCP) [23 (link)], Harris and Benedict (HarrisBenedict) [24 (link)], Ireton-Jones et al. (IretonJones) [25 (link)], Faisy et al. (FaisyFagon) [26 (link)], Müller et al. (Müller) [27 (link)], and Frankenfield et al. (PennState) [28 (link)]. The PE were chosen as representative of their derivation cohort (none: ACCP; healthy: HarrisBenedict, Müller; ICU patients: FaisyFagon, PennState), and the type and number of contained variables: simplified equations including one static variable (ACCP); equations including ≥1 static variable (HarrisBenedict, IretonJones, Müller); PE including ≥1 static and additional dynamic variables (FaisyFagon and PennState). If appropriate, formula-specific correction factors (e.g., stress, trauma, burns) were used.
Burns
Calorimetry, Indirect
Carbohydrates
Consciousness
Critical Illness
Dialysis
Eligibility Determination
Exhaling
Fistula
Hemodynamics
Hemofiltration
Inhalation
Mechanical Ventilation
Medical Devices
Nipple Discharge
Outpatients
Oxygen
Patients
Pharmaceutical Preparations
physiology
Respiratory Rate
Sedatives
Therapeutics
Tidal Volume
Vasoconstrictor Agents
Wounds and Injuries
We conducted a single-centre retrospective cohort study evaluating admissions to the Royal Free Hospital London with acute decompensation (AD) of liver cirrhosis, from October 2018 to February 2021.
Admissions with decompensated cirrhosis were identified from inpatient records including ward lists, electronic patient records and hospital endoscopy reporting software (Unisoft). Data were collected using medical notes, laboratory, radiology and histology reports, clinic letters, discharge summaries and endoscopy reports. Data collected included patient demographics; aetiology of liver disease; precipitant of decompensation event; type of decompensation event; prior decompensation history; length of hospital stay; blood test results (admission, including admission to the intensive treatment unit (ITU) if applicable and discharge) and the presence of infection and/or spontaneous bacterial peritonitis (SBP) and COVID-19 status, which was determined by a PCR test on admission. In addition, physiological parameters and observations such as blood pressure, oxygen saturation by pulse oximetry (%) and fraction of inspired oxygen at admission were also recorded. For admissions involving stays in intensive care, data were collected on use of mechanical ventilation, inotropic support and haemofiltration Supplemental data were collected on patients requiring interventional procedures including abdominal paracentesis, endoscopy, liver biopsy and transhepatic portosystemic shunts (TIPSS). For patients requiring paracentesis between admissions, the frequency of paracentesis was recorded in intervals of weeks. Dates of death and/or liver transplantation were recorded for patients meeting these outcomes within the study period. Data were collected for all included patients throughout the study period with 6-month follow-up data obtained. Attempts were made to reduce the following sets of bias: information and selection bias by using multiple record systems to maximise data capture and minimise missing data, and confounding bias through multivariate analysis.
The following severity scores were calculated; UK Model for End-Stage Liver Disease, Model for End-Stage Liver Disease-Sodium and Child Pugh Score. Definitions from the European Association for the Study of the Liver Chronic Liver Failure Consortium (CLIF-C) were used to calculate CLIF-C OF scores and to establish the presence of ACLF. For patients without ACLF, CLIF-C AD scores on admission and discharge were recorded.5 (link)
Admissions with decompensated cirrhosis were identified from inpatient records including ward lists, electronic patient records and hospital endoscopy reporting software (Unisoft). Data were collected using medical notes, laboratory, radiology and histology reports, clinic letters, discharge summaries and endoscopy reports. Data collected included patient demographics; aetiology of liver disease; precipitant of decompensation event; type of decompensation event; prior decompensation history; length of hospital stay; blood test results (admission, including admission to the intensive treatment unit (ITU) if applicable and discharge) and the presence of infection and/or spontaneous bacterial peritonitis (SBP) and COVID-19 status, which was determined by a PCR test on admission. In addition, physiological parameters and observations such as blood pressure, oxygen saturation by pulse oximetry (%) and fraction of inspired oxygen at admission were also recorded. For admissions involving stays in intensive care, data were collected on use of mechanical ventilation, inotropic support and haemofiltration Supplemental data were collected on patients requiring interventional procedures including abdominal paracentesis, endoscopy, liver biopsy and transhepatic portosystemic shunts (TIPSS). For patients requiring paracentesis between admissions, the frequency of paracentesis was recorded in intervals of weeks. Dates of death and/or liver transplantation were recorded for patients meeting these outcomes within the study period. Data were collected for all included patients throughout the study period with 6-month follow-up data obtained. Attempts were made to reduce the following sets of bias: information and selection bias by using multiple record systems to maximise data capture and minimise missing data, and confounding bias through multivariate analysis.
The following severity scores were calculated; UK Model for End-Stage Liver Disease, Model for End-Stage Liver Disease-Sodium and Child Pugh Score. Definitions from the European Association for the Study of the Liver Chronic Liver Failure Consortium (CLIF-C) were used to calculate CLIF-C OF scores and to establish the presence of ACLF. For patients without ACLF, CLIF-C AD scores on admission and discharge were recorded.5 (link)
Abdomen
ARNTL2 protein, human
Bacteria
Biopsy
Blood Pressure
Child
COVID 19
Endoscopy, Gastrointestinal
End Stage Liver Disease
Europeans
Hematologic Tests
Hemofiltration
Infection
Inpatient
Intensive Care
Liver
Liver Cirrhosis
Liver Diseases
Liver Failure, Acute
Liver Function Tests
Liver Transplantations
Mechanical Ventilation
Oximetry, Pulse
Oxygen
Oxygen Saturation
Paracentesis
Patient Discharge
Patients
Peritonitis
physiology
Sodium
Surgical Portosystemic Shunt
X-Rays, Diagnostic
Top products related to «Hemofiltration»
Sourced in Japan, Belgium
The CAPIOX® FX05 is a blood oxygenator and heat exchanger designed for use in extracorporeal circulation. It is a core component of the cardiopulmonary bypass system used during cardiac surgery.
Sourced in United States, United Kingdom, Denmark, Austria
Stata is a general-purpose statistical software package for data analysis, data management, and graphics. It provides a wide range of data manipulation, statistical, and graphical tools to help researchers and analysts effectively analyze and visualize data.
Sourced in United States
The Aquarius hemodialysis system is a medical device designed for the treatment of end-stage renal disease. It is used to perform hemodialysis, a process that removes waste, salt, and excess water from the blood when the kidneys are unable to do so.
Sourced in Germany
Unfractionated heparin is an anticoagulant medication used to prevent and treat blood clots. It is a complex mixture of sulfated polysaccharides derived from animal sources, primarily porcine intestinal mucosa.
Sourced in Germany
The Diapact CRRT is a continuous renal replacement therapy (CRRT) device designed for the treatment of acute kidney injury. It provides automated control and monitoring of blood and dialysate/replacement fluid flow rates, temperature, and pressure during CRRT procedures.
Sourced in Germany
The Poly sulfone membrane is a key component in various laboratory equipment and devices. It serves as a highly permeable barrier, enabling the selective separation and filtration of different molecules and particles. The membrane's structure and material properties allow for efficient filtration and processing of fluids and solutions in diverse laboratory applications.
Sourced in Germany
The MultiFiltrate is a blood purification device used in renal replacement therapy. It is designed to filter and remove waste, electrolytes, and excess fluid from the blood. The MultiFiltrate utilizes a semi-permeable membrane to selectively filter and control the balance of substances in the bloodstream.
Sourced in Japan
The DX-100 is a multi-parameter patient monitor developed by Nihon Kohden. It is designed to continuously measure and display various physiological parameters, including ECG, respiration, and oxygen saturation. The DX-100 is intended for use in various healthcare settings, such as hospitals and clinics, to assist medical professionals in patient monitoring and care.
Sourced in Japan
The TR 55X is a lab equipment product manufactured by Toray. It is designed for scientific and research applications. The core function of the TR 55X is to perform precise measurements and analysis. The detailed specifications and intended use of this product are not available in this response.
Sourced in Japan
The CH‐1.8 W is a laboratory equipment product manufactured by Toray. It is a compact device designed for specific laboratory applications. The core function of the CH‐1.8 W is to perform precise measurements and analyses, though its detailed capabilities are not included in this factual description.
More about "Hemofiltration"
Hemofiltration, also known as continuous venovenous hemofiltration (CVVH), is a type of renal replacement therapy (RRT) that utilizes a semipermeable membrane to remove waste products, excess water, and electrolytes from the blood.
This process is often employed to treat acute kidney injury (AKI) or chronic kidney disease (CKD).
Compared to hemodialysis, hemofiltration can provide more precise control over fluid balance and electrolyte levels, making it a valuable alternative.
Researchers in this field may leverage AI-driven platforms like PubCompare.ai to optimize their hemofiltration research process.
PubCompare.ai enables researchers to locate the best protocols from literature, preprints, and patents, enhancing the reproducibility and accuracy of their studies.
By exploring the power of PubCompare.ai, researchers can take their hemofiltration research to the next level.
In the context of hemofiltration, other relevant terms and technologies include CAPIOX® FX05, a blood oxygenation system; Stata software, a statistical analysis tool; the Aquarius hemodialysis system; Unfractionated heparin, an anticoagulant; the Diapact CRRT system; Polysulfone membranes, a common material used in hemofiltration filters; MultiFiltrate, a CRRT device; the DX-100 hemofiltration machine; and the TR 55X and CH‐1.8 W, which are hemofiltration devices.
Leveraging these technologies and tools can further optimize the hemofiltration research process and improve patient outcomes.
This process is often employed to treat acute kidney injury (AKI) or chronic kidney disease (CKD).
Compared to hemodialysis, hemofiltration can provide more precise control over fluid balance and electrolyte levels, making it a valuable alternative.
Researchers in this field may leverage AI-driven platforms like PubCompare.ai to optimize their hemofiltration research process.
PubCompare.ai enables researchers to locate the best protocols from literature, preprints, and patents, enhancing the reproducibility and accuracy of their studies.
By exploring the power of PubCompare.ai, researchers can take their hemofiltration research to the next level.
In the context of hemofiltration, other relevant terms and technologies include CAPIOX® FX05, a blood oxygenation system; Stata software, a statistical analysis tool; the Aquarius hemodialysis system; Unfractionated heparin, an anticoagulant; the Diapact CRRT system; Polysulfone membranes, a common material used in hemofiltration filters; MultiFiltrate, a CRRT device; the DX-100 hemofiltration machine; and the TR 55X and CH‐1.8 W, which are hemofiltration devices.
Leveraging these technologies and tools can further optimize the hemofiltration research process and improve patient outcomes.